Licensing status

Publication and contact information

Drug platforms

Injectable extracellular matrix (ECM) hydrogel for treating heart failure following myocardial infarction (MI)

An injectable, porcine-derived ECM hydrogel could be useful for treating MI. In a porcine model for MI, catheter-mediated delivery of the ECM hydrogel decreased pathological left ventricular remodeling and increased cardiac function compared with delivery of saline. In rats, the hydrogel was biodegradable and biocompatible. In human blood samples, the hydrogel was hemo-compatible and triggered minimal platelet activation. Next steps include scaled-up GMP manufacturing of the clinical-grade version of the hydrogel, called VentriGel.
Ventrix Inc.'s VentriGel is in preclinical development to prevent left ventricular remodeling and reduce heart failure following MI (see VentriGel goes into pigs, page 10).

SciBX 6(10); doi:10.1038/scibx.2013.250
Published online March 14, 2013

Patents pending; licensed to Ventrix; available for partnering from Ventrix

Seif-Naraghi, S.B. et al. Sci. Transl. Med.; published online
Feb. 20, 2013;
Contact: Karen L. Christman, University of California, San Diego, La Jolla, Calif.